CNS drugs

Keyphrases

Publications

volume 38, number 7, 2024

Jian-Shun Zhou, Zhen Chen, Ying-Ying Liu, Mao-Lin Zhong, Qiong Zhong, Jun Wei, Qian Hu, Jia-Sheng Wang, Li-Feng Wang
Observation on the Analgesic Effect of Different Doses of a Combination of Esketamine and Dexmedetomidine Administered for Percutaneous Endoscopic Transforaminal Discectomy: A Randomized, Double-Blind Controlled Trial. CNS drugs 38 (7) (2024)
Megan Galbally, Karen Wynter, Dan J Siskind, Christoph U Correll, Korinne Northwood, Susanna Every-Palmer
Sex Differences Between Female and Male Individuals in Antipsychotic Efficacy and Adverse Effects in the Treatment of Schizophrenia. CNS drugs 38 (7) (2024)
Nazia Karsan, Peter J Goadsby
Intervening in the Premonitory Phase to Prevent Migraine: Prospects for Pharmacotherapy. CNS drugs 38 (7) (2024)
Adrián Gucký, Slavka Hamulakova
Targeting Biometals in Alzheimer's Disease with Metal Chelating Agents Including Coumarin Derivatives. CNS drugs 38 (7) (2024)
Nazia Karsan, Peter J Goadsby
Intervening in the Premonitory Phase to Prevent Migraine: Prospects for Pharmacotherapy. CNS drugs 38 (7) (2024)
Michael H Rosenbloom, Tricia O'Donohue, Domi Zhou-Clark, Deepashni Mala, Andrew Frazier, Michael Tarrant, Michelle Modrijan, Melora Riveira, Darla Chapman, Yvonne Griffin, Lauren Shakalis, Thomas J Grabowski
A Framework for the Administration of Anti-amyloid Monoclonal Antibody Treatments in Early-Stage Alzheimer's Disease. CNS drugs 38 (7) (2024)
Michael H Rosenbloom, Tricia O'Donohue, Domi Zhou-Clark, Deepashni Mala, Andrew Frazier, Michael Tarrant, Michelle Modrijan, Melora Riveira, Darla Chapman, Yvonne Griffin, Lauren Shakalis, Thomas J Grabowski
A Framework for the Administration of Anti-amyloid Monoclonal Antibody Treatments in Early-Stage Alzheimer's Disease. CNS drugs 38 (7) (2024)
Megan Galbally, Karen Wynter, Dan J Siskind, Christoph U Correll, Korinne Northwood, Susanna Every-Palmer
Sex Differences Between Female and Male Individuals in Antipsychotic Efficacy and Adverse Effects in the Treatment of Schizophrenia. CNS drugs 38 (7) (2024)
Adrián Gucký, Slavka Hamulakova
Targeting Biometals in Alzheimer's Disease with Metal Chelating Agents Including Coumarin Derivatives. CNS drugs 38 (7) (2024)
Michael H Rosenbloom, Tricia O'Donohue, Domi Zhou-Clark, Deepashni Mala, Andrew Frazier, Michael Tarrant, Michelle Modrijan, Melora Riveira, Darla Chapman, Yvonne Griffin, Lauren Shakalis, Thomas J Grabowski
A Framework for the Administration of Anti-amyloid Monoclonal Antibody Treatments in Early-Stage Alzheimer's Disease. CNS drugs 38 (7) (2024)
Adrián Gucký, Slavka Hamulakova
Targeting Biometals in Alzheimer's Disease with Metal Chelating Agents Including Coumarin Derivatives. CNS drugs 38 (7) (2024)
Megan Galbally, Karen Wynter, Dan J Siskind, Christoph U Correll, Korinne Northwood, Susanna Every-Palmer
Sex Differences Between Female and Male Individuals in Antipsychotic Efficacy and Adverse Effects in the Treatment of Schizophrenia. CNS drugs 38 (7) (2024)
Orwa Albitar, Sabariah Noor Harun, Siti Maisharah Sheikh Ghadzi
Semi-physiological Pharmacokinetic Model of Clozapine and Norclozapine in Healthy, Non-smoking Volunteers: The Impact of Race and Genetics. CNS drugs 38 (7) (2024)

volume 38, number 8, 2024

Jeffrey L Cummings, Amanda M Leisgang Osse, Jefferson W Kinney, Davis Cammann, Jingchun Chen
Alzheimer's Disease: Combination Therapies and Clinical Trials for Combination Therapy Development. CNS drugs 38 (8) (2024)
John M Kane, Roy Eshet, Eran Harary, Orna Tohami, Anna Elgart, Helena Knebel, Nir Sharon, Mark Suett, Kelli R Franzenburg, Glen L Davis, Christoph U Correll
A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical Trial. CNS drugs 38 (8) (2024)
Jeffrey L Cummings, Amanda M Leisgang Osse, Jefferson W Kinney, Davis Cammann, Jingchun Chen
Alzheimer's Disease: Combination Therapies and Clinical Trials for Combination Therapy Development. CNS drugs 38 (8) (2024)
Liliana Patarroyo-Rodriguez, Stefanie Cavalcanti, Jennifer L Vande Voort, Balwinder Singh
The Use of Ketamine for the Treatment of Anhedonia in Depression. CNS drugs 38 (8) (2024)
John M Kane, Roy Eshet, Eran Harary, Orna Tohami, Anna Elgart, Helena Knebel, Nir Sharon, Mark Suett, Kelli R Franzenburg, Glen L Davis, Christoph U Correll
A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical Trial. CNS drugs 38 (8) (2024)
Teppei Kouga, Toru Miwa, Kishiko Sunami, Yoshiaki Itoh
Effectiveness of Anti-Calcitonin Gene-Related Peptide Medication in Vestibular Migraine: A Retrospective Cohort Study in an Asian Population. CNS drugs 38 (8) (2024)
Teppei Kouga, Toru Miwa, Kishiko Sunami, Yoshiaki Itoh
Effectiveness of Anti-Calcitonin Gene-Related Peptide Medication in Vestibular Migraine: A Retrospective Cohort Study in an Asian Population. CNS drugs 38 (8) (2024)
Jeffrey L Cummings, Amanda M Leisgang Osse, Jefferson W Kinney, Davis Cammann, Jingchun Chen
Alzheimer's Disease: Combination Therapies and Clinical Trials for Combination Therapy Development. CNS drugs 38 (8) (2024)
Hui-Ling Qu, Xiao-Yu Sun, Chao He, Hui-Sheng Chen
Sex Differences in the Dual Antiplatelet Therapy Versus Alteplase for Patients with Minor Nondisabling Acute Ischemic Stroke: A Secondary Analysis of the ARAMIS Study. CNS drugs 38 (8) (2024)
Jeffrey L Cummings, Amanda M Leisgang Osse, Jefferson W Kinney, Davis Cammann, Jingchun Chen
Alzheimer's Disease: Combination Therapies and Clinical Trials for Combination Therapy Development. CNS drugs 38 (8) (2024)
Anca Maglaviceanu, Miki Peer, Jason Rockel, Robert P Bonin, Mary-Ann Fitzcharles, Karim S Ladha, Anuj Bhatia, Timothy Leroux, Lakshmi Kotra, Mohit Kapoor, Hance A Clarke
The State of Synthetic Cannabinoid Medications for the Treatment of Pain. CNS drugs 38 (8) (2024)
John M Kane, Roy Eshet, Eran Harary, Orna Tohami, Anna Elgart, Helena Knebel, Nir Sharon, Mark Suett, Kelli R Franzenburg, Glen L Davis, Christoph U Correll
A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical Trial. CNS drugs 38 (8) (2024)

volume 38, number 9, 2024

Clément Garnier, Martin Schein, Clémence Lacroix, Elisabeth Jouve, Thomas Soeiro, Gaétan Gentile, Maryse Lapeyre Mestre, Joëlle Micallef
Patterns of Pregabalin Users from Substance Abuse Treatment Facilities: Results from the French OPPIDUM Program from 2008 to 2022. CNS drugs 38 (9) (2024)
Kingsley Wong, Mohammed Junaid, Solomon Alexander, Heather E Olson, Elia M Pestana-Knight, Rajsekar R Rajaraman, Jenny Downs, Helen Margaret Leonard
Caregiver Perspective of Benefits and Side Effects of Anti-Seizure Medications in CDKL5 Deficiency Disorder from an International Database. CNS drugs 38 (9) (2024)
Yaroslav Winter, Raya Abou Dargham, Susana Patiño Tobón, Sergiu Groppa, Sven Fuest
Cenobamate as an Early Adjunctive Treatment in Drug-Resistant Focal-Onset Seizures: An Observational Cohort Study. CNS drugs 38 (9) (2024)
Hubertus Himmerich, Jessica Bentley, Susan L McElroy
Pharmacological Treatment of Binge Eating Disorder and Frequent Comorbid Diseases. CNS drugs 38 (9) (2024)
Yaroslav Winter, Raya Abou Dargham, Susana Patiño Tobón, Sergiu Groppa, Sven Fuest
Cenobamate as an Early Adjunctive Treatment in Drug-Resistant Focal-Onset Seizures: An Observational Cohort Study. CNS drugs 38 (9) (2024)
Yaroslav Winter, Raya Abou Dargham, Susana Patiño Tobón, Sergiu Groppa, Sven Fuest
Cenobamate as an Early Adjunctive Treatment in Drug-Resistant Focal-Onset Seizures: An Observational Cohort Study. CNS drugs 38 (9) (2024)
Clément Garnier, Martin Schein, Clémence Lacroix, Elisabeth Jouve, Thomas Soeiro, Gaétan Gentile, Maryse Lapeyre Mestre, Joëlle Micallef
Patterns of Pregabalin Users from Substance Abuse Treatment Facilities: Results from the French OPPIDUM Program from 2008 to 2022. CNS drugs 38 (9) (2024)
Mishal Qubad, Gabriele Dupont, Martina Hahn, Simon S Martin, Valentina O Puntmann, Eike Nagel, Andreas Reif, Robert A Bittner
When, Why and How to Re-challenge Clozapine in Schizophrenia Following Myocarditis. CNS drugs 38 (9) (2024)
Mishal Qubad, Gabriele Dupont, Martina Hahn, Simon S Martin, Valentina O Puntmann, Eike Nagel, Andreas Reif, Robert A Bittner
When, Why and How to Re-challenge Clozapine in Schizophrenia Following Myocarditis. CNS drugs 38 (9) (2024)
Hubertus Himmerich, Jessica Bentley, Susan L McElroy
Pharmacological Treatment of Binge Eating Disorder and Frequent Comorbid Diseases. CNS drugs 38 (9) (2024)
Clément Garnier, Martin Schein, Clémence Lacroix, Elisabeth Jouve, Thomas Soeiro, Gaétan Gentile, Maryse Lapeyre Mestre, Joëlle Micallef
Patterns of Pregabalin Users from Substance Abuse Treatment Facilities: Results from the French OPPIDUM Program from 2008 to 2022. CNS drugs 38 (9) (2024)
Kingsley Wong, Mohammed Junaid, Solomon Alexander, Heather E Olson, Elia M Pestana-Knight, Rajsekar R Rajaraman, Jenny Downs, Helen Margaret Leonard
Caregiver Perspective of Benefits and Side Effects of Anti-Seizure Medications in CDKL5 Deficiency Disorder from an International Database. CNS drugs 38 (9) (2024)
Emmanuelle Andree Danielle Schindler
Psychotropic Drugs Reemerging as Headache Medicines. CNS drugs 38 (9) (2024)
Yaroslav Winter, Raya Abou Dargham, Susana Patiño Tobón, Sergiu Groppa, Sven Fuest
Cenobamate as an Early Adjunctive Treatment in Drug-Resistant Focal-Onset Seizures: An Observational Cohort Study. CNS drugs 38 (9) (2024)
Kingsley Wong, Mohammed Junaid, Solomon Alexander, Heather E Olson, Elia M Pestana-Knight, Rajsekar R Rajaraman, Jenny Downs, Helen Margaret Leonard
Caregiver Perspective of Benefits and Side Effects of Anti-Seizure Medications in CDKL5 Deficiency Disorder from an International Database. CNS drugs 38 (9) (2024)
Kingsley Wong, Mohammed Junaid, Solomon Alexander, Heather E Olson, Elia M Pestana-Knight, Rajsekar R Rajaraman, Jenny Downs, Helen Margaret Leonard
Caregiver Perspective of Benefits and Side Effects of Anti-Seizure Medications in CDKL5 Deficiency Disorder from an International Database. CNS drugs 38 (9) (2024)
Emmanuelle Andree Danielle Schindler
Psychotropic Drugs Reemerging as Headache Medicines. CNS drugs 38 (9) (2024)
Yaroslav Winter, Raya Abou Dargham, Susana Patiño Tobón, Sergiu Groppa, Sven Fuest
Cenobamate as an Early Adjunctive Treatment in Drug-Resistant Focal-Onset Seizures: An Observational Cohort Study. CNS drugs 38 (9) (2024)
Kingsley Wong, Mohammed Junaid, Solomon Alexander, Heather E Olson, Elia M Pestana-Knight, Rajsekar R Rajaraman, Jenny Downs, Helen Margaret Leonard
Caregiver Perspective of Benefits and Side Effects of Anti-Seizure Medications in CDKL5 Deficiency Disorder from an International Database. CNS drugs 38 (9) (2024)
Emmanuelle Andree Danielle Schindler
Psychotropic Drugs Reemerging as Headache Medicines. CNS drugs 38 (9) (2024)
Mishal Qubad, Gabriele Dupont, Martina Hahn, Simon S Martin, Valentina O Puntmann, Eike Nagel, Andreas Reif, Robert A Bittner
When, Why and How to Re-challenge Clozapine in Schizophrenia Following Myocarditis. CNS drugs 38 (9) (2024)
Mishal Qubad, Gabriele Dupont, Martina Hahn, Simon S Martin, Valentina O Puntmann, Eike Nagel, Andreas Reif, Robert A Bittner
When, Why and How to Re-challenge Clozapine in Schizophrenia Following Myocarditis. CNS drugs 38 (9) (2024)
Hubertus Himmerich, Jessica Bentley, Susan L McElroy
Pharmacological Treatment of Binge Eating Disorder and Frequent Comorbid Diseases. CNS drugs 38 (9) (2024)
Mishal Qubad, Gabriele Dupont, Martina Hahn, Simon S Martin, Valentina O Puntmann, Eike Nagel, Andreas Reif, Robert A Bittner
When, Why and How to Re-challenge Clozapine in Schizophrenia Following Myocarditis. CNS drugs 38 (9) (2024)
Clément Garnier, Martin Schein, Clémence Lacroix, Elisabeth Jouve, Thomas Soeiro, Gaétan Gentile, Maryse Lapeyre Mestre, Joëlle Micallef
Patterns of Pregabalin Users from Substance Abuse Treatment Facilities: Results from the French OPPIDUM Program from 2008 to 2022. CNS drugs 38 (9) (2024)